HIV Cure Scientific Working Group
The latent reservoir represents the fundamental problem to an HIV-1 cure. Successful therapy requires lifelong treatment. The major, and perhaps only, reservoir of latent virus is in resting CD4+ T-cells. An important focus of current research efforts is developing strategies to reduce the burden of reactivateable virus, with the ultimate goal of eradicating this reservoir.
The HIV Cure Scientific Working Group achieves its goals by addressing specific questions representing roadblocks in achieving a cure. The goal is to generate new paths of research that can be pursued by young investigators and senior investigators who want to move in to the HIV field, and collaboration among established investigators to develop new interdisciplinary approaches.
Leaders of the CFAR HIV Cure Scientific Working Group hold leadership positions in one of the NIH Delaney Collaboratories (CARE) and the recent UNC-GSK HIV Cure Center. UNC Chapel Hill has a strong research portfolio in studies of chromatin modification and regulation of gene expression, as well as drug discovery. This is fertile ground for a Scientific Working Group that brings together experts in cure research in the public and private sector with researchers in related fields with the goal of exploring new paths of inquiry and developing the next generation of researchers.
David Margolis, MD
Dr. David Margolis is the director of the UNC HIV Cure Center and a professor in both the Division of Infectious Diseases and the Department of Epidemiology. His laboratory has a long history of translational HIV research: investigating basic molecular, virological and immunological phenomenon, and leveraging insights to develop new interventions in HIV disease. While his work has involved many aspects of HIV science and medicine, for the last two decades a central focus has been the study of molecular mechanisms of HIV proviral latency and persistence despite potent antiretroviral therapy (ART).
He has begun to define the role of epigenetic factors in the restriction of HIV expression; this has led to diverse, multidisciplinary collaborations and translational clinical studies resulting in discovery and high-impact work. He is the principal investigator for CARE (Collaboratory of AIDS Researchers for Eradication), an NIH-funded U19 research organization that seeks to develop the tools to bring an HIV cure from the bench to the clinic.
For inquiries, please contact Prema Menezes
In the News